Marie Plante

Université Laval

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Marie‐Claude Renaud

Université de Montréal

Jean‐Pierre Grégoire

Université Laval

Michel Roy

Centre Hospitalier Universitaire de Saint-Étienne

Alexandra Sebastianelli

Université Laval

Bernard Têtu

Centre hospitalier universitaire de Québec

Janice S. Kwon

University of British Columbia

Dimcho Bachvarov

Université Laval

Vanessa Samouëlian

Centre Hospitalier de l’Université de Montréal

Katherine Grondin

Université Laval

Limor Helpman

Tel Aviv University

Cooperative Institutions

Université Laval

173

Centre hospitalier universitaire de Québec

137

Gynecologic Oncology Group

115

University of British Columbia

112

University College London

107

University of Toronto

102

Memorial Sloan Kettering Cancer Center

100

Princess Margaret Cancer Centre

Inserm

The University of Texas MD Anderson Cancer Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression

Gynecologic Oncology (2012)

Mamadou Keita Zhiqiang Wang Jean‐François Pelletier Magdalena Bachvarova Marie Plante

Serous ovarian cancer

Tumor progression

10.1016/j.ygyno.2012.11.036

Cite

Citations (56)

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Oncology (2017)

Éric Pujade-Lauraine Jonathan A. Ledermann Frédèric Selle Val Gebski Richard T. Penson

Olaparib

BRCA Mutation

PARP inhibitor

Clinical endpoint

10.1016/s1470-2045(17)30469-2

Cite

Citations (1,657)

Estimation risk of lymph nodal invasion in patients with early-stage cervical cancer: Cervical cancer application

Frontiers in Oncology (2022)

Benedetta Guani Thomas Gaillard Ly-Ann Teo-Fortin Vincent Balaya Anis Féki

Lymph node status is a major prognostic factor in early-stage cervical cancer. Predicting the risk of lymph node metastasis is essential for optimal therapeutic management. The aim of the study was to develop a web-based application to predict the risk of lymph node metastasis in patients with early-stage (IA1 with positive lymph vascular space invasion, IA2 and IB1) cervical cancer.We performed a secondary analysis of data from two prospective multicenter trials, Senticol 1 and 2 pooled together in the training dataset. The histological risk factors were included in a multivariate logistic regression model in order to determine the most suitable prediction model. An internal validation of the chosen prediction model was then carried out by a cross validation of the 'leave one out cross validation' type. The prediction model was implemented in an interactive online application of the 'Shinyapp' type. Finally, an external validation was performed with a retrospective cohort from L'Hôtel-Dieu de Québec in Canada.Three hundred twenty-one patients participating in Senticol 1 and 2 were included in our training analysis. Among these patients, 280 did not present lymph node invasion (87.2%), 13 presented isolated tumor cells (4%), 11 presented micrometastases (3.4%) and 17 macrometastases (5.3%). Tumor size, presence of lymph-vascular space invasion and stromal invasion were included in the prediction model. The Receiver Operating Characteristic (ROC) Curve from this model had an area under the curve (AUC) of 0.79 (95% CI [0.69- 0.90]). The AUC from the cross validation was 0.65. The external validation on the Canadian cohort confirmed a good discrimination of the model with an AUC of 0.83.This is the first study of a prediction score for lymph node involvement in early-stage cervical cancer that includes internal and external validation. The web application is a simple, practical, and modern method of using this prediction score to assist in clinical management.

10.3389/fonc.2022.935628

Cite

Citations (2)

Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers

Human Mutation (2012)

Susan J. Ramus Antonis C. Antoniou Karoline B. Kuchenbaecker Penny Soucy Jonathan Beesley

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67-0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21-1.83) P-trend = 1.8 × 10(-4), rs717852 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.6 × 10(-4), rs9303542 HR = 1.16 (95% CI: 1.02-1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81-0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.1 × 10(-4). The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer.

Genome-wide Association Study

10.1002/humu.22025

Cite

Citations (36)

Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.

PubMed (1993)

Marie Plante Gabriel Wong Jerome S. Nisselbaum Lois Almadrones W.J. Hoskins

To determine the distribution of saliva CA 125 levels in women with and without ovarian cancer, and to determine whether there is a correlation between saliva and serum CA 125 levels in either group.CA 125 levels were measured by immunoradiometric assay in the serum and saliva of 50 women with epithelial ovarian cancer known to have elevated serum CA 125 levels (above 35 U/mL) and in 50 women seen for benign gynecologic conditions.Serum and saliva CA 125 values followed a log-normal distribution in both groups. The medians for serum and saliva CA 125 levels in cancer patients were 578 and 1379 U/mL, respectively. In the benign group, the median CA 125 value was 11 U/mL in serum and 994 U/mL in saliva. The correlation between saliva and serum CA 125 levels was not statistically significant in either the cancer (r = 0.003) or the benign group (r = 0.025).There is no relationship between saliva and serum CA 125 levels in women with either epithelial ovarian cancer or benign gynecologic conditions.

Immunoradiometric assay

Source

Cite

Citations (8)

Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women

Frontiers in Endocrinology (2018)

Yannick Audet-Delage Laurent Villeneuve Jean‐Pierre Grégoire Marie Plante Chantal Guillemette

Endometrial cancer (EC) is the most frequent gynecological cancer in developed countries. Most EC occurs after menopause and is diagnosed as endometrioid (type I) carcinomas, which exhibit a favorable prognosis. In contrast, non-endometrioid (type II) carcinomas such as serous tumors have a poor prognosis. Our goal was to identify novel blood-based markers associated with EC subtypes and recurrence after surgery in postmenopausal women. Using mass spectrometry-based untargeted metabolomics, we examined preoperative serum metabolites among control women (n = 18) and those with non-recurrent (NR) and recurrent (R) cases of type I endometrioid (n = 24) and type II serous (n = 12) carcinomas. R and NR cases were similar with respect to pathological characteristics, body mass index and age. A total of 1592 compounds were analyzed including 14 different lipid classes. When we compared EC cases with controls, 137 metabolites were significantly different. A combination of spermine and isovalerate resulted in an age-adjusted area under the receiver-operating characteristic curve (AUCadj) of 0.914 (P < 0.001) for EC detection. The combination of 2-oleoylglycerol and TAG42:2-FA12:0 allowed the distinction of R cases from NR cases with an AUCadj of 0.901 (P < 0.001). Type I R cases were also characterized by much lower levels of bile acids and elevated concentrations of phosphorylated fibrinogen cleavage peptide, whereas type II R cases displayed higher levels of ceramides. The findings from our pilot study provide a detailed metabolomics study of EC and identify putative serum biomarkers for defining clinically relevant risk groups.

SDHA

10.3389/fendo.2018.00087

Cite

Citations (41)

0194: Efficacy of Peglyated Liposomal Doxorubicin (PLD) Plus Carboplatin in Patients with Partially Sensitive Relapsing Advanced Ovarian Cancer

International Journal of Gynecological Cancer (2006)

Patti Power Gavin Stuart Amit M. Oza Diane Provencher J. Bentley

Carboplatin

10.1136/ijgc-00009577-200610001-00194

Cite

Citations (0)

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Journal of Clinical Oncology (2006)

Jacobus Pfisterer Marie Plante Ignace Vergote Andreas du Bois Hal W. Hirte

Most patients with advanced ovarian cancer develop recurrent disease. For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel; however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation. Thus, an alternative regimen without significant neurotoxicity was evaluated by comparing gemcitabine plus carboplatin with single-agent carboplatin in platinum-sensitive recurrent ovarian cancer patients.Patients with platinum-sensitive recurrent ovarian cancer were randomly assigned to receive either gemcitabine plus carboplatin or carboplatin alone, every 21 days. The primary objective was to compare progression-free survival (PFS).Three hundred fifty-six patients (178 gemcitabine plus carboplatin; 178 carboplatin) were randomly assigned. Patients received a median of six cycles in both arms. With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin. The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031). Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016). The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349). While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon. No statistically significant differences in quality of life scores between arms were noted.Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.

Carboplatin

Regimen

10.1200/jco.2006.06.0913

Cite

Citations (743)

Erratum: Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium

Journal of Gynecologic Oncology (2023)

Ngoc Phan Quy T. Tran Nhan P. T. Nguyen Hang Thu Nguyen Linh D.N. Tran

This corrects the article on p. e88 in vol. 34, PMID: 37668081.

Gynecologic cancer

10.3802/jgo.2023.34.e89

Cite

Citations (0)

ST-elevation myocardial infarction after thrombolytic therapy with Tenecteplase for acute ischaemic stroke

BMJ Case Reports (2023)

JORGE SINCLAIR DE FRÍAS Marie Plante Michael F. Harrison Devang Sanghavi

Myocardial infarction (MI) secondary to thrombolytic therapy in the setting of acute ischaemic stroke (AIS) is a rare but severe complication. This phenomenon has been well documented in the past with recombinant tissue-type plasminogen activator, also known as Alteplase. However, there are no documented reports of MI secondary to Tenecteplase (TNKase), an alternative thrombolytic agent rapidly gaining favour in managing AIS. We report a male patient in his 50s who received TNKase for an AIS and subsequently developed an inferolateral ST elevation MI.

Tenecteplase

Ischaemic stroke

Fibrinolytic agent

ST elevation

Stroke

10.1136/bcr-2022-252253

Cite

Citations (1)